OLDWICK, N.J., June 29, 2020 /PRNewswire/ -- Provention Bio,
Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated diseases, today
announced that it has been added to the broad-market Russell
3000® Index and the small-cap Russell 2000® Index as part
of the Russell US Indexes annual reconstitution.
Annual Russell indexes reconstitution captures the 4,000 largest
US stocks as of May 8, 2020 ranking
them by total market capitalization. Membership in the US all-cap
Russell 3000® Index, which remains in place for one year,
means automatic inclusion in the large-cap Russell 1000® Index
or small-cap Russell 2000® Index as well as the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets are benchmarked against
Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
For more information on the Russell 3000® Index and the
Russell indexes reconstitution, go to the "Russell Reconstitution"
section on the FTSE Russell website.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company leveraging a transformational drug development strategy
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to source, transform and develop
therapeutic candidates targeting the high morbidity, mortality and
escalating costs of autoimmune diseases. Provention's diversified
portfolio includes teplizumab, a pre-commercial-stage candidate
that has been shown to delay the onset of insulin-dependent type 1
diabetes (T1D) in at-risk patients during the presymptomatic phase
of the disease. The Company's portfolio includes additional
clinical product development candidates that have
demonstrated proof-of-mechanism and/or proof-of-concept
in other autoimmune diseases, including celiac disease and
lupus.
Investor Contact:
Sam
Martin, Argot Partners
Sam@argotpartners.com
212-600-1902
Media:
Lori Rosen, LDR
Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-inclusion-in-the-russell-3000-index-and-russell-2000-index-301084534.html
SOURCE Provention Bio, Inc.